healthcare professional for medical advice
incomplete av block
urgent revascularization
black tarry stool
pleural effusion
frequent micturition
embolism
gp
peripheral coldness
wound
datum
pale skin
bleed increase
bronchospasm
tingle of hand
identify bleed site
dopamine
anxiety
abciximab
spontaneous gross hematuria
femoral artery introducer
haca
gi
cardiovascular
gastroesophageal reflux
igg
complete av block
ptca procedure
epilog
anemia
lower baseline hemoglobin
hyperkalemia
formation of human anti chimeric antibody
pci
pulmonary embolism
spontaneous hematemesis
pulmonary hemorrhage
nsteac
stomach discomfort
ami
intracranial bleeding
woman
pseudoaneurysm
indigestion
emergency
lightheadedness
epinephrine
intracranial hemorrhage
sneeze
medical attention
chest pain
vomit
blur vision
hypesthesia
ige
foot
retroperitoneal
irregular heartbeat
excess spontaneous major organ bleeding
group
nausea
health care professional
history of copd
dyspepsia
diplopia
red spot on skin
great care
cause of more
nodal arrhythmia
major hemorrhage
acute coronary syndrome
repeat revascularization
tightness in chest
myocardial infarction
dizziness
control group
glycoprotein
minor bleeding
femoral artery access site
incidence of major bleeding event from gi
datum from the thrombolysis
abdominal pain
heartburn
cabg
major bleeding
limb
rate
recent puncture site
diabetes mellitus
abciximab treated group
hemorrhage
troubled breathing
fear
bruise
immediate discontinuation of abciximab
thrombocytopenia
belch
undergo percutaneous coronary intervention
itch
involve acute myocardial infarction
greater incidence of major
stool
inflammation
undergo pcus
musculoskeletal pain
medicine
rale
administer heparin
back pain
body
sit position
accord
burn
hyperesthesia
confusion
asthenia
sour stomach
mood
change in vision
cough
benign laboratory condition
tirofiban
coma
healthy volunteer
muscle contraction
bleed gum
bleed
active ingredient
manufacturer
heparin
cystalgia
antiplatelet activity
coronary artery bypass graft
observe blood loss with a hemoglobin decrease of greater than g dl
numbness
crawl
unusual tiredness
bronchitis
pruritus
swell of hand
place
readministration
adjunctive abciximab
antibody
event of serious bleeding
urinary retention
fda
clinical significance of a positive haca titer
arteriovenous fistula
incidence of pseudothrombocytopenia
pin
researcher
pseudothrombocytopenia
dementia
gi system
injection site pain
duration of gp iib iiia inhibitor infusion
acute myocardial infarction
petechiae
angioplasty
theophylline
binding
sore throat
renal dysfunction
sweating
general feeling of illness
tami
compression
dry mouth
addition
higher risk
peripheral vascular disease
agitation
incision pain
mental change
palpitation
pleurisy
iib iiia inhibitor
myalgia in less
man
rapid weight gain
aspirin
faintness
wheeze
transfusion
needle
abnormal thinking
indwell
ankle
cellulitis
abnormal vision
eye pain
greater incidence of major bleeding episode
july
pain
angioplasty in myocardial infarction
reopro
case
urgent ptca
hypotension
ventricular tachycardia
risk for minor bleeding
weigh kg
incidence of haca formation
risk of intracranial
arterial access guideline
prostatitis
pneumonia
transfusion of blood product
decrease in hemoglobin
non treated group
headache
major bleeding episode
gp iib iiia receptor
nervousness
pain at the puncture site
use of weight adjust abciximab infusion
baseline platelet count
give
ptca
fatal bleeding event
delusion
rhonchus
leukocytosis
potential benefit of readministration of abciximab
stroke
anaphylaxis
hypertonia
blood in urine
abnormal chest x ray at baseline
cell mcl
fold increase
pallor
increase sweating
acid
develop
tingle feeling
author
readministration of abciximab
get
diarrhea
other site
risk factor
prior history of gi disease
peripheral edema
undergo coronary intervention
unusual bleeding
weakness
g dl
thromboembolism
nervous system
chill
dysuria
human anti chimeric antibody
bullous eruption
fever
gp iib iiia inhibitor
greater risk of bleeding than man
lie
ileus
common site of bleeding
incidence
abnormal renal function
least g dl without a
require transfusion
discomfort
peak
female gender
tract
date
immune globulin
use abciximab
response
fatality
diabetes
enlarged abdomen
lower body weight
placebo
e
major bleeding event
shortness of breath
i
antihistamine
protein solution
venous line
pharmacokinetic disposition of abciximab
analysis
prickle
early removal of the femoral sheath
platelet count
excessive dosing
lower leg
urinary incontinence
bradycardia